Shareholder Alert: Ademi LLP investigates whether NextGen Healthcare, Inc. has obtained a Fair Price in its transaction with Thoma Bravo

MILWAUKEE, Sept. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating NextGen Healthcare (Nasdaq: NXGN) for possible breaches of fiduciary duty and other violations of law in its transaction with Thoma Bravo.

Click here to learn how to join the action https://www.ademilaw.com/case/nextgen-healthcare-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, NextGen Healthcare stockholders are expected to receive only $23.95 per share. The transaction agreement unreasonably limits competing transactions for NextGen Healthcare by imposing a significant penalty if NextGen Healthcare accepts a competing bid. NextGen Healthcare insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of NextGen Healthcare's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own NextGen Healthcare common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/nextgen-healthcare-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP